Skip to main content
. 2020 Aug 18;47(11):1257–1266. doi: 10.1111/1346-8138.15514

Figure 4.

Figure 4

Treatment pattern and course in each patient. In this figure, complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) represent the best overall response in each patient. IPI, ipilimumab; irAE, immune‐related adverse event; NE, not evaluable; NIVO, nivolumab.